Constellation Pharmaceuticals, Inc. (CNST:NASDAQ) Annual Reports & Investor Relations Material

Overview

Constellation Pharmaceuticals is a biopharmaceutical company working to address unmet medical needs in cancer patients by selectively modulating gene expression. The company's focus is on epigenetic and chromatin modifications in cancer cells and tumor microenvironments. Constellation is currently developing CPI-0610, a BET inhibitor for myelofibrosis, and CPI-0209, an EZH2 inhibitor for solid tumors. The company is also exploring other novel targets that impact gene expression to build a diverse pipeline of small-molecule product candidates.

Annual Reports

Frequently Asked Questions

What is Constellation Pharmaceuticals, Inc.'s ticker?

Constellation Pharmaceuticals, Inc.'s ticker is CNST

What exchange is Constellation Pharmaceuticals, Inc. traded on?

The company's shares trade on the NASDAQ stock exchange

Where are Constellation Pharmaceuticals, Inc.'s headquarters?

They are based in Cambridge, Massachusetts

How many employees does Constellation Pharmaceuticals, Inc. have?

There are 51-200 employees working at Constellation Pharmaceuticals, Inc.

What is Constellation Pharmaceuticals, Inc.'s website?

It is https://www.constellationpharma.com/

What type of sector is Constellation Pharmaceuticals, Inc.?

Constellation Pharmaceuticals, Inc. is in the Healthcare sector

What type of industry is Constellation Pharmaceuticals, Inc.?

Constellation Pharmaceuticals, Inc. is in the Biotechnology industry

Who are Constellation Pharmaceuticals, Inc.'s peers and competitors?

The following five companies are Constellation Pharmaceuticals, Inc.'s industry peers:

- INmune Bio

- Acceleron Pharma Inc.

- Cytori Therapeutics

- Verrica Pharmaceuticals Inc.

- Protagonist Therapeutics, Inc.